The Effects of Pharmacologic Agents for Type 2 Diabetes Mellitus on Body Weight

References

• National Institutes of Health. Type 2 diabetes fact sheet. http://www.nih.gov/about/researchresultsforthepublic/Type2Diabetes.pdf. Accessed December 10, 2007.
   Google Scholar
• Centers for Disease Control and Prevention. National diabetes fact sheet. http://apps.nccd.cdc.gov/DDTSTRS/FactSheet.aspx. 2005. Accessed December 10, 2007.
   Google Scholar
• Centers for Disease Control and Prevention. Diabetes: disabling disease to double by 2050. http://www.cdc.gov/nccdphp/publications/aag/ddt.htm. 2007. Accessed December 10, 2007.
   Google Scholar
• Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999–2004. JAMA. 2006; 295(13): 1549–1555.
   PubMed Web of Science ®Google Scholar
• Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999–2000. JAMA. 2002; 288(14): 1723–1727.
   PubMed Web of Science ®Google Scholar
• Palamara KL, Mogul HR, Peterson SJ, Frishman WH. Obesity: new perspectives and pharmacotherapies. Cardiol Rev. 2006; 14(5): 238–258.
   PubMedGoogle Scholar
• Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999–2002. JAMA. 2004; 291(23): 2847–2850.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Diabetes: public health GIS news and information. November 2004. http://www.cdc.gov/search.do?q=129.6+overweight&spell=1&ie=utf8. Accessed December 10, 2007.
   Google Scholar
• Rappaport EB, Usher DC. Obesity, insulin resistance, and type 2 diabetes in children and adolescents. Pediatr Ann. 2006; 35(11): 822–826.
   PubMed Web of Science ®Google Scholar
• Pincock S, Zimmet P. Fighting the “diabesity” pandemic. Lancet. 2006; 368(9548): 1643.
   PubMed Web of Science ®Google Scholar
• Sims EA, Danforth E Jr, Horton ES, Bray GA, Glennon JA, Salans LB. Endocrine and metabolic effects of experimental obesity in man. Recent Prog Horm Res. 1973; 29: 457–496.
   PubMedGoogle Scholar
• Hart CL, Hole DJ, Lawlor DA, Davey Smith G. How many cases of type 2 diabetes mellitus are due to being overweight in middle age? Evidence from the mid span prospective cohort studies using mention of diabetes mellitus on hospital discharge or death records. Diabet Med. 2007; 24(1): 73–80.
   PubMed Web of Science ®Google Scholar
• Narayan KM, Boyle JP, Thompson TJ, Gregg EW, Williamson DF. Effect of BMI on lifetime risk for diabetes in the U.S. Diabetes Care. 2007; 30(6): 1562–1566.
   PubMed Web of Science ®Google Scholar
• Wannamethee SG, Shaper AG, Walker M. Overweight and obesity and weight change in middle aged men: impact on cardiovascular disease and diabetes. J Epidemiol Community Health. 2005; 59(2): 134–139.
   PubMed Web of Science ®Google Scholar
• Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world—a growing challenge. N Engl J Med. 2007; 356(3): 213–215.
   PubMed Web of Science ®Google Scholar
• Field AE, Coakley EH, Must A, et al. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med. 2001; 161 (13): 1581–1586.
   PubMedGoogle Scholar
• Montague CT, O'Rahilly S. The perils of portliness: causes and consequences of visceral adiposity. Diabetes. 2000; 49(6): 883–888.
   PubMed Web of Science ®Google Scholar
• Alberti KG, Zimmet P, Shaw J. The metabolic syndrome-a new worldwide definition. Lancet. 2005; 366(9491): 1059–1062.
   PubMed Web of Science ®Google Scholar
• Hogan P, Dali T, Nikolov P. Economic costs of diabetes in the US in 2002. Diabetes Care. 2003; 26(3): 917–932.
   PubMed Web of Science ®Google Scholar
• Colclough H, Hammer, M. Impact of increasing body mass index on medical resources for patients with type 2 diabetes: a retrospective analysis in the United States. ISPOR Annual European Congress in Dublin (EuroISPOR). 2007: Poster PDB48.
   Google Scholar
• Colclough H, Aagren M, Milligan G. Impact on health care cost of increasing body mass index for people with type 2 diabetes: a cross- sectional study in United States. ISPOR Annual European Congress in Dublin (EuroISPOR). 2007: Poster PDB55.
   Google Scholar
• Wilson PW, Kannel WB, Silbershatz H, D'Agostino RB. Clustering of metabolic factors and coronary heart disease. Arch Intern Med. 1999; 159(10): 1104–1109.
   PubMed Web of Science ®Google Scholar
• Manson JE, Colditz GA, Stampfer MJ, et al. A prospective study of obesity and risk of coronary heart disease in women. N Engl J Med. 1990; 322(13): 882–889.
   PubMed Web of Science ®Google Scholar
• Haffner SM. Relationship of metabolic risk factors and development of cardiovascular disease and diabetes. Obesity (Silver Spring). 2006; 14(supp1 3): 121S–127S.
   Google Scholar
• Wannamethee SG, Shaper AG, Whincup PH, Walker M. Role of risk factors for major coronary heart disease events with increasing length of follow up. Heart. 1999; 81(4): 374–379.
   PubMed Web of Science ®Google Scholar
• Pekkanen J, Tervahauta M, Nissinen A, Karvonen MJ. Does the predictive value of baseline coronary risk factors change over a 30-year follow-up? Cardiology:. 1993; 82(2–3): 181–190.
   PubMed Web of Science ®Google Scholar
• Bailey CJ. Drugs on the horizon for diabesity. Curr Diah Rep. 2005; 5(5): 353–359.
   PubMedGoogle Scholar
• Thomas J, Jones G, Scarinci I, Brantley P. A descriptive and comparative study of the prevalence of depressive and anxiety disorders in low-income adults with type 2 diabetes and other chronic illnesses. Diabetes Care. 2003; 26(8): 2311–2317.
   PubMed Web of Science ®Google Scholar
• Egede LE. Effect of comorbid chronic diseases on prevalence and odds of depression in adults with diabetes. Psychosom Med. 2005; 67(1): 46 51.
   PubMed Web of Science ®Google Scholar
• Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care. 2001; 24(6): 1069–1078.
   PubMed Web of Science ®Google Scholar
• Fava M. Weight gain and antidepressants. J Clin Psychiatry. 2000; 61(supp1 11): 37–41.
   PubMedGoogle Scholar
• Williams B. The obese hypertensive: the weight of evidence against beta-blockers. Circulation. 2007; 115(15): 1973–1974.
   PubMed Web of Science ®Google Scholar
• Haslam DW, James WP. Obesity. Lancet. 2005; 366(9492): 1197–1209.
   PubMed Web of Science ®Google Scholar
• Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999; 281 (21): 2005–2012.
   PubMed Web of Science ®Google Scholar
• Maggio CA, Pi-Sunyer FX. Obesity and type 2 diabetes. Endocrinol Metab Clin North Am. 2003, 32(4): 805–822, viii.
   PubMed Web of Science ®Google Scholar
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131): 837–853.
   PubMed Web of Science ®Google Scholar
• Norris SL, Zhang X, Avenell A, et al. Long-term non-pharmacological weight loss interventions for adults with type 2 diabetes. Cochrane Database Syst Rev. 2005; (2): CD004095.
   Google Scholar
• Vermiere E, Wens J, Van Royen P, Biot Y, Heamshaw H, Lindenmeyer A. Interventions for improving adherence to treatment recommendations in people with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2005; (2): CD003638.
   Google Scholar
• Saaddine JB, Cadwell B, Gregg EW, et al. Improvements in diabetes processes of care and intermediate outcomes: United States, 1988–2002. Ann Intern Med. 2006; 144(7): 465–174.
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy—update regarding the thiazolidinediones. Diabetologia. 2008; 51(1): 8–11.
   PubMed Web of Science ®Google Scholar
• AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007; 13(supp1 1): 168.
   Google Scholar
• Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA. 2002; 287(3): 360–372.
   PubMed Web of Science ®Google Scholar
• Turner RC. The UK Prospective Diabetes Study. A review. Diabetes Care. 1998; 21(supp1 3): C35–C38.
   Google Scholar
• Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA. 2000; 283(13): 1695–1702.
   PubMed Web of Science ®Google Scholar
• Fonseca VA, Valiquett TR, Huang SM, Ghazzi MN, Whitcomb RW. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group. J Clin Endocrinol Metab. 1998; 83(9): 3169–3176.
   PubMed Web of Science ®Google Scholar
• Lebovitz HE. Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metab Res Rev. 2002; 18(supp1 2): S23–S29.
   Google Scholar
• Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care. 2001; 24(7): 1226–1232.
   PubMed Web of Science ®Google Scholar
• Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care. 2000; 23(11): 1605–1611.
   PubMed Web of Science ®Google Scholar
• Horton ES, Whitehouse F, Ghazzi MN, Venable TC, Whitcomb RW. Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group. Diabetes Care. 1998; 21(9): 1462–1469.
   PubMed Web of Science ®Google Scholar
• Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med. 2001; 111(1): 10–17.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Goldstein BJ, Vinik AI, et al. Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SUL phonylurea Titration (RESULT) study. Diabetes Obes Metab. 2006; 8(1): 49–57.
   PubMed Web of Science ®Google Scholar
• Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PRO active Study (PRO spective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005; 366(9493): 1279–1289.
   PubMed Web of Science ®Google Scholar
• Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006; 355(23): 2427–2443.
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Yusuf S, Bosch J, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006; 368(9541): 1096–1105.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Manufacturers of some diabetes drugs to strengthen warning on heart failure risk, http://www.fda.gov/bbs/topics/NEWS/2007/NEW01683.html. Accessed January 16, 2008.
   Google Scholar
• Carlson MG, Campbell PJ. Intensive insulin therapy and weight gain in IDDM. Diabetes. 1993; 42(12): 1700–1707.
   PubMed Web of Science ®Google Scholar
• Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int JObes. 2002; 26(supp1 3 J: S18–S24.
   Google Scholar
• Meneghini LF, Rosenberg KH, Koenen C, Merilainen MJ, Luddeke HJ. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. Diabetes Obes Metab. 2007; 9(3): 418–427.
   PubMed Web of Science ®Google Scholar
• Haak T, Tiengo A, Draeger E, Suntum M, Waldhaus W. Lower within- subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab. 2005; 7(1): 56–64.
   PubMed Web of Science ®Google Scholar
• Raslova K, Tamer SC, Clauson P, Karl D. Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index. Clin Drug Investig. 2007; 27(4): 279–285.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia. 2008; 51(3): 408–416.
   PubMed Web of Science ®Google Scholar
• Hermansen K, Davies M. Does insulin detemir have a role in reducing risk of insulin-associated weight gain? Diabetes Obes Metab. 2007; 9(3): 209–217.
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006; 29(8): 1963–1972.
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidy1 peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006; 368(9548): 1696–1705.
   PubMed Web of Science ®Google Scholar
• Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986; 29(1): 46–52.
   PubMed Web of Science ®Google Scholar
• Orskov C, Wettergren A, Holst JJ. Biological effects and metabolic rates of glucagonlike peptide-1 7–36 amide and glucagonlike peptide-1 7–37 in healthy subjects are indistinguishable. Diabetes. 1993; 42(5): 658–61.
   PubMed Web of Science ®Google Scholar
• Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007; 298(2): 194–206.
   PubMed Web of Science ®Google Scholar
• Byetta [package insert]. San Diego, CA: Amylin Pharmaceuticals; 2007.
   Google Scholar
• Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004; 27(11): 2628–2635.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005; 28(5): 1092–1100.
   PubMed Web of Science ®Google Scholar
• Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005; 28(5): 1083–1091.
   PubMed Web of Science ®Google Scholar
• Naslund E, Gutniak M, Skogar S, Rossner S, Hellstrom PM. Glucagonlike peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. Am J Clin Nutr. 1998; 68(3): 525–530.
   PubMed Web of Science ®Google Scholar
• Gutzwiller JP, Drewe J, Goke B, et al. Glucagonlike peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol. 1999; 276(5 pt 2): R1541–R1544.
   PubMed Web of Science ®Google Scholar
• Buse JB, Klonoff DC, Nielsen LL, et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open- label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther. 2007; 29(1): 139–153.
   PubMed Web of Science ®Google Scholar
• Kim D, MacConell L, Zhuang D, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care. 2007; 30(6): 1487–1493.
   PubMed Web of Science ®Google Scholar
• Agerso H, Jensen LB, Elbrond B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia. 2002; 45(2): 195–202.
   PubMed Web of Science ®Google Scholar
• Chang AM, Jakobsen G, Sturis J, et al. The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes. 2003; 52(7): 1786–1791.
   PubMed Web of Science ®Google Scholar
• Degn KB, Juhl CB, Sturis J, et al. One week's treatment with the long- acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes. 2004; 53(5): 1187–1194.
   PubMed Web of Science ®Google Scholar
• Vilsboll T, Zdravkovic M, Le-Thi T, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care. 2007; 30(6): 1608–1610.
   PubMed Web of Science ®Google Scholar
• Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care. 2004; 27(6): 1335–1342.
   PubMed Web of Science ®Google Scholar
• Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007; 132(6): 2131–2157.
   PubMed Web of Science ®Google Scholar
• Januvia [package insert]. Whitehouse Station, NJ: Merck and Co., Inc.; 2007.
   Google Scholar
• Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy and safety of the dipeptidy1 peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006; 29(12): 2638–2643.
   PubMed Web of Science ®Google Scholar
• Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE. Effect of the dipeptidy1 peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006; 29(12): 2632–2637.
   PubMed Web of Science ®Google Scholar
• Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE. Effect of initial combination therapy with sitagliptin, a dipeptidy1 peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 2007; 30(8): 1979–1987.
   PubMed Web of Science ®Google Scholar
• Novartis. Galvus, a new oral treatment for type 2 diabetes, receives positive opinion following changes to European prescribing information. http://cws.huginonline.eom/N/134323/PRy200712/1176484_5_2.html. Accessed January 14, 2008.
   Google Scholar
• Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract. 2007; 76(1): 132 138.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Baron MA, Camisasca RP, Cressier F, Couturier A, Dejager S. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab. 2007; 9(2): 175–185.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care. 2007; 30(2): 217–223.
   PubMed Web of Science ®Google Scholar
• Schweizer A, Couturier A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naive patients with Type 2 diabetes. Diabet Med. 2007; 24(9): 955–961.
   PubMed Web of Science ®Google Scholar
• Weyer C, Maggs DG, Young AA, Kolterman OG. Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control. Curr Pharm Des. 2001; 7(14): 1353–1373.
   PubMed Web of Science ®Google Scholar
• Hollander P, Maggs DG, Ruggles JA, et al. Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obes Res. 2004; 12(4): 661–668.
   PubMedGoogle Scholar
• Riddle M, Frias J, Zhang B, et al. Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin. Diabetes Care. 2007; 30(11): 2794–2799.
   PubMed Web of Science ®Google Scholar
• Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ. 2007; 335(7631): 1194–1199.
   PubMed Web of Science ®Google Scholar
• Dixon JB, O'Brian PB, Playfair PE, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized control trial. JAMA. 2008; 299(3): 316–323.
   PubMed Web of Science ®Google Scholar
• Hauptman JB, Jeunet FS, Hartmann D. Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18–0647 (tetrahydrolipstatin). Am J Clin Nutr. 1992; 55(1 supp1): 309S–313S.
   Web of Science ®Google Scholar
• Huizinga M. Weight-loss pharmacotherapy: a brief review. Clinical Diabetes. 2007; 25(4): 135–140.
   Google Scholar
• Guy-Grand B, Drouin P, Eschwege E, Gin H, Joubert JM, Valensi P. Effects of orlistat on obesity-related diseases—a six-month randomized trial. Diabetes Obes Metab. 2004; 6(5): 375–383.
   PubMed Web of Science ®Google Scholar
• Kelley DE, Bray GA, Pi-Sunyer FX, Klein S, Hill J, Miles J, Hollander P. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial. Diabetes Care. 2002; 25(6): 1033–1041.
   PubMed Web of Science ®Google Scholar
• Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1 -year randomized double-blind study. Diabetes Care. 1998; 21 (8): 1288–1294.
   PubMed Web of Science ®Google Scholar
• Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet. 2007: 369(9555): 71–77.
   PubMed Web of Science ®Google Scholar
• Padwal R, Li SK, Lau DCW. Long-term pharmacotherapy for overweight and obesity. Int J Obes Relal Metab Disord. 2003; 27(12): 1437–1446.
   PubMed Web of Science ®Google Scholar
• Padwal RS, Li SK, Lau DCW. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev. 2003; (4): CD004094.
   Google Scholar
• European Medicines Agency. Xenical scientific discussion. 2005. Available at: http://www.emea.eu.int/humandocs/PDFs/EPAR/Xenical/106698en6.pdf. Accessed December 10, 2007.
   Google Scholar
• McNeely W, Goa KL. Sibutramine: a review of its contribution to the management of obesity. Drugs. 1998; 56(6): 1093–1124.
   PubMed Web of Science ®Google Scholar
• .Connoley IP, Liu YL, Frost I, Reckless IP, Heal DJ. Stock MJ. Thermogenic effects of sibutramine and its metabolites. Br J Pharmacol. 1999; 126(6): 1487–495.
   PubMed Web of Science ®Google Scholar
• Lean ME. How does sibutramine work? Int J Obes Relat Metab Disord. 2001; 25(supp1 4): S8–S11.
   PubMedGoogle Scholar
• Vettor R, Serra R, Fabris R, Pagano C, Federspil G. Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies. Diabetes Care. 2005; 28(4): 942–949.
   PubMed Web of Science ®Google Scholar
• Wooltorton E. Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias. CMAJ. 2002; 166(10): 1307–1308.
   PubMed Web of Science ®Google Scholar
• Henness S, Robinson DM, Lyseng-Williamson KA. Rimonabant. Drugs. 2006; 66(16): 2109–2121.
   PubMedGoogle Scholar
• Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet. 2006; 368(9548): 1660–1672.
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA. 2006; 295(7): 761–775.
   PubMed Web of Science ®Google Scholar
• Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet. 2007; 370(9600): 1706–1713.
   PubMed Web of Science ®Google Scholar
• PR Newswire. Rimonabant regulatory update in the United States. Published June 29, 2007. http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/06-29-2007/0004618254&EDATF= Accessed December 10, 2007.
   Google Scholar
• Sjostrom L, Narbro K, Sjostrom CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007; 357(8): 741–752.
   PubMed Web of Science ®Google Scholar
• Jones KB. Experience with the Roux-en-Y gastric bypass and commentary on current trends. Obes Surg. 2000; 10(2): 183–185.
   PubMed Web of Science ®Google Scholar
• Adams TD, Gress RE. Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007; 357(8): 753–761.
   PubMed Web of Science ®Google Scholar
• Diniz MF, Diniz MT, Sanches SR, Salgado PP, Valadao MM, Freitas CP, Vieira DJ. Glycemic control in diabetic patients after bariatric surgery. Obes Surg. 2004; 14(8): 1051–1055.
   PubMed Web of Science ®Google Scholar
• Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-loywering drugs in insulin-naive people with type 2 diabetes. Diabetes Care. 2006, 29(6): 1269–1274.
   PubMed Web of Science ®Google Scholar
• Bloomgarden ZT. Prevention of obesity and diabetes. Diabetes Care. 2003; 26(11): 3172–3178.
   PubMed Web of Science ®Google Scholar
• Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001; 344(18): 1343–1350.
   PubMed Web of Science ®Google Scholar
• Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346(6): 393–403.
   PubMed Web of Science ®Google Scholar